NCT05167071 - HBM4003 Combine With Toripalimab in Patients With Advanced NEN and Other Solid Tumors Study | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 28, 2021

Primary Completion Date

September 30, 2025

Study Completion Date

June 30, 2026

Conditions

Solid TumorsNeuroendocrine TumorsCRC

Interventions

DRUG

HBM4003

Subjects will be treated with HBM4003 on Day 1 during each 21-day cycle.

DRUG

Toripalimab

Subjects will be treated with Toripalimab on Day 1 during each 21-day cycle.

DRUG

Tislelizumab

Subjects will be treated with Tislelizumab on Day 1 during each 21-day cycle.

Trial Locations (1)

Beijing Cancer Hospital, Beijing

All Listed Sponsors

lead

Harbour BioMed (Guangzhou) Co. Ltd.

INDUSTRY